Patents by Inventor Young-Guen Kwon
Young-Guen Kwon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220152067Abstract: The present invention relates to a cancer immunotherapy adjuvant, wherein the adjuvant, when administered in combination with a cancer immunotherapy agent, activates the function of immune factors without causing in vivo side effects, to exhibit the effect of enhancing the kit for anticancer effect of the cancer immunotherapy agent, and thus can be effectively used as a cancer immunotherapy adjuvant.Type: ApplicationFiled: April 23, 2020Publication date: May 19, 2022Inventors: Young-Guen KWON, Haiying ZHANG, Songyi PARK, Minyoung NOH, Yeomyeong KIM, Myung-Hwa KIM, Koo Hyeon AHN, Jung-In PYO
-
Patent number: 10125183Abstract: The present invention provides a decoy peptide or polypeptide capable of inhibiting the binding of AMIGO2 and 3-phosphoinositide-dependent kinase 1 (PDK1), and a pharmaceutical composition, containing the decoy peptide or polypeptide as an active ingredient, for preventing or treating cancer or an angiogenic disease. Furthermore, the present invention provides a method for screening a material for preventing or treating cancer or an angiogenic disease. According to the present invention, it is worth noting that the decoy peptide or polypeptide of the present invention induces apoptosis through the inhibition of the binding of AMIGO2 and 3-phosphoinositide-dependent kinase 1 (PDK1); reduces migration and adhesion of endothelial cells; significantly reduces vascular induction, survival, and growth.Type: GrantFiled: June 28, 2016Date of Patent: November 13, 2018Assignee: Curacle Co., Ltd.Inventors: Young Guen Kwon, Hyo Jin Park
-
Publication number: 20160376339Abstract: The present invention provides a decoy peptide or polypeptide capable of inhibiting the binding of AMIGO2 and 3-phosphoinositide-dependent kinase 1 (PDK1), and a pharmaceutical composition, containing the decoy peptide or polypeptide as an active ingredient, for preventing or treating cancer or an angiogenic disease. Furthermore, the present invention provides a method for screening a material for preventing or treating cancer or an angiogenic disease. According to the present invention, it is worth noting that the decoy peptide or polypeptide of the present invention induces apoptosis through the inhibition of the binding of AMIGO2 and 3-phosphoinositide-dependent kinase 1 (PDK1); reduces migration and adhesion of endothelial cells; significantly reduces vascular induction, survival, and growth.Type: ApplicationFiled: June 28, 2016Publication date: December 29, 2016Inventors: Young Guen KWON, Hyo Jin PARK
-
Patent number: 9381168Abstract: The present invention relates to a new use of capsiate or dihydrocapsiate, more particularly to a composition for preventing and treating inflammatory disease, angiogenesis-related disease and autoimmune disease or for suppressing immunity comprising capsiate, dihydrocapsiate or a pharmaceutically acceptable salt thereof as an effective ingredient. The composition and immunosuppressant of the present invention may be used for preventing and treating inflammatory disease, angiogenesis-related disease and autoimmune disease, and for suppressing immunity.Type: GrantFiled: May 27, 2008Date of Patent: July 5, 2016Assignee: Catholic University Industry Academy Cooperation FoundationInventors: Dong Heun Shin, Young Guen Kwon, Bo Jeong Pyun, Tae-Yoon Kim
-
Patent number: 9249220Abstract: The present invention relates to human monoclonal antibodies neutralizing vascular endothelial growth factor receptor and the use thereof. More specifically, relates to human ScFv molecules neutralizing vascular endothelial growth factor receptor, and a composition for inhibiting angiogenesis and a composition for treating cancer, which contain the human ScFv molecules. The disclosed monoclonal antibody neutralizing vascular endothelial growth factor receptor shows excellent neutralizing ability in living cells, compared to that of a commercially available antibody against vascular endothelial growth factor receptor, and shows the ability to neutralize vascular endothelial growth factor receptor not only in humans, but also in mice and rats. Thus, the monoclonal antibody will be useful in anticancer studies and will be highly effective in cancer treatment.Type: GrantFiled: March 11, 2014Date of Patent: February 2, 2016Assignee: PHARMABCINE INC.Inventors: Jin-San Yoo, Weon-Sup Lee, Sang-Ryeol Shim, Mi-Hee Park, Jeong-Eun Kang, Do-Yun Kim, Joon-Chul Lee, Dong-Heon Lee, Too-Hyon Cho, Sam-Sook Sul, Young-Guen Kwon, Bo-Jeong Pyun, Kwi-Hwa Kim, Chae-Ok Yun, Nahm-Ju Kim, Jae-Won Jeon, Dong-Sup Lee, Young-Woo Park, Geun-Bae Rha, Hyun-Sook Jang, Hyeon-Mi Yoo, Sung-Woo Kim, Semi Kim, Sang-Seok Koh
-
Patent number: 9249219Abstract: The present invention relates to human monoclonal antibodies neutralizing vascular endothelial growth factor receptor and the use thereof. More specifically, relates to human ScFv molecules neutralizing vascular endothelial growth factor receptor, and a composition for inhibiting angiogenesis and a composition for treating cancer, which contain the human ScFv molecules. The disclosed monoclonal antibody neutralizing vascular endothelial growth factor receptor shows excellent neutralizing ability in living cells, compared to that of a commercially available antibody against vascular endothelial growth factor receptor, and shows the ability to neutralize vascular endothelial growth factor receptor not only in humans, but also in mice and rats. Thus, the monoclonal antibody will be useful in anticancer studies and will be highly effective in cancer treatment.Type: GrantFiled: March 11, 2014Date of Patent: February 2, 2016Assignee: PHARMABCINE INC.Inventors: Jin-San Yoo, Weon-Sup Lee, Sang-Ryeol Shim, Mi-Hee Park, Jeong-Eun Kang, Do-Yun Kim, Joon-Chul Lee, Dong-Heon Lee, Too-Hyon Cho, Sam-Sook Sul, Young-Guen Kwon, Bo-Jeong Pyun, Kwi-Hwa Kim, Chae-Ok Yun, Nahm-Ju Kim, Jae-Won Jeon, Dong-Sup Lee, Young-Woo Park, Geun-Bae Rha, Hyun-Sook Jang, Hyeon-Mi Yoo, Sung-Woo Kim, Semi Kim, Sang-Seok Koh
-
Patent number: 9241973Abstract: A pharmaceutical composition for regenerating an endothelial cell which includes as an active ingredient a DKK2 protein or a polynucleotide encoding the DKK2 protein, a pharmaceutical composition for preventing or treating erectile dysfunction, a method of regenerating an endothelial cell of a subject and a method of preventing or treating erectile dysfunction of a subject and which treat or prevent erectile dysfunction in a subject.Type: GrantFiled: April 10, 2012Date of Patent: January 26, 2016Assignee: INHA INDUSTRY PARTNERSHIP INSTITUTEInventors: Jun Kyu Suh, Ji Kan Ryu, Hai Rong Jin, Young Guen Kwon
-
Patent number: 9150650Abstract: The present invention relates to human monoclonal antibodies neutralizing vascular endothelial growth factor receptor and the use thereof. More specifically, relates to human ScFv molecules neutralizing vascular endothelial growth factor receptor, and a composition for inhibiting angiogenesis and a composition for treating cancer, which contain the human ScFv molecules. The disclosed monoclonal antibody neutralizing vascular endothelial growth factor receptor shows excellent neutralizing ability in living cells, compared to that of a commercially available antibody against vascular endothelial growth factor receptor, and shows the ability to neutralize vascular endothelial growth factor receptor not only in humans, but also in mice and rats. Thus, the monoclonal antibody will be useful in anticancer studies and will be highly effective in cancer treatment.Type: GrantFiled: June 26, 2007Date of Patent: October 6, 2015Assignee: PHARMABCINE INC.Inventors: Jin-San Yoo, Weon-Sup Lee, Sang-Ryeol Shim, Mi-Hee Park, Jeong-Eun Kang, Do-Yun Kim, Joon Chul Lee, Dong-Heon Lee, Too-Hyon Cho, Sam-Sook Sul, Young-Guen Kwon, Bo-Jeong Pyun, Kwi-Hwa Kim, Chae-Ok Yun, Nahm-Ju Kim, Jae-Won Jeon, Dong-Sup Lee, Young-Woo Park, Geun-Bae Rha, Hyun-Sook Jang, Hyeon-Mi Yoo, Sung-Woo Kim, Se-mi Kim, Sang-Seok Koh
-
Patent number: 8889840Abstract: The present disclosure relates to a novel vascular leakage inhibitor. The novel vascular leakage inhibitor of the present disclosure inhibits the apoptosis of vascular endothelial cells, inhibits the formation of actin stress fibers induced by VEGF, enhances the cortical actin ring structure, and improves the stability of the tight junctions (TJs) between vascular cells, thereby inhibiting vascular leakage. The vascular leakage inhibitor of the present disclosure has the activity of not only reducing vascular permeability but also recovering the integrity of damaged blood vessels. Accordingly, the vascular leakage inhibitor of the present disclosure can prevent or treat various diseases caused by vascular leakage. Since the vascular leakage inhibitor of the present disclosure is synthesized from commercially available or easily synthesizable cholesterols, it has remarkably superior feasibility of commercial synthesis.Type: GrantFiled: October 29, 2010Date of Patent: November 18, 2014Assignee: Industry-Academic Cooperation Foundation, Yonsei UniversityInventors: Young-Guen Kwon, Young-Ger Suh
-
Publication number: 20140288274Abstract: The present invention relates to human monoclonal antibodies neutralizing vascular endothelial growth factor receptor and the use thereof. More specifically, relates to human ScFv molecules neutralizing vascular endothelial growth factor receptor, and a composition for inhibiting angiogenesis and a composition for treating cancer, which contain the human ScFv molecules. The disclosed monoclonal antibody neutralizing vascular endothelial growth factor receptor shows excellent neutralizing ability in living cells, compared to that of a commercially available antibody against vascular endothelial growth factor receptor, and shows the ability to neutralize vascular endothelial growth factor receptor not only in humans, but also in mice and rats. Thus, the monoclonal antibody will be useful in anticancer studies and will be highly effective in cancer treatment.Type: ApplicationFiled: March 11, 2014Publication date: September 25, 2014Inventors: Jin-San Yoo, Weon-Sup Lee, Sang-Ryeol Shim, Mi-Hee Park, Jeong-Eun Kang, Do-Yun Kim, Joon-Chul Lee, Dong-Heon Lee, Too-Hyon Cho, Sam-Sook Sul, Young-Guen Kwon, Bo-Jeong Pyun, Kwi-Hwa Kim, Chae-Ok Yun, Nahm-Ju Kim, Jae-Won Jeon, Dong-Sup Lee, Young-Woo Park, Geun-Bae Rha, Hyun-Sook Jang, Hyeon-Mi Yoo, Sung-Woo Kim, Semi Kim, Sang-Seok Koh
-
Publication number: 20140275488Abstract: The present invention relates to human monoclonal antibodies neutralizing vascular endothelial growth factor receptor and the use thereof. More specifically, relates to human ScFv molecules neutralizing vascular endothelial growth factor receptor, and a composition for inhibiting angiogenesis and a composition for treating cancer, which contain the human ScFv molecules. The disclosed monoclonal antibody neutralizing vascular endothelial growth factor receptor shows excellent neutralizing ability in living cells, compared to that of a commercially available antibody against vascular endothelial growth factor receptor, and shows the ability to neutralize vascular endothelial growth factor receptor not only in humans, but also in mice and rats. Thus, the monoclonal antibody will be useful in anticancer studies and will be highly effective in cancer treatment.Type: ApplicationFiled: March 11, 2014Publication date: September 18, 2014Applicant: PHARMABCINE INC.Inventors: Jin-San YOO, Weon-Sup Lee, Sang-Ryeol Shim, Mi-Hee Park, Jeong-Eun Kang, Do-Yun Kim, Joon-Chul Lee, Dong-Heon Lee, Too-Hyon Cho, Sam-Sook Sul, Young-Guen Kwon, Bo-Jeong Pyun, Kwi-Hwa Kim, Chae-Ok Yun, Nahm-Ju Kim, Jae-Won Jeon, Dong-Sup Lee, Young-Woo Park, Geun-Bae Rha, Hyun-Sook Jang, Hyeon-Mi Yoo, Sung-Woo Kim, Semi Kim, Sang-Seok Koh
-
Publication number: 20140235527Abstract: A pharmaceutical composition for regenerating an endothelial cell which includes as an active ingredient a DKK2 protein or a polynucleotide encoding the DKK2 protein, a pharmaceutical composition for preventing or treating erectile dysfunction, a method of regenerating an endothelial cell of a subject and a method of preventing or treating erectile dysfunction of a subject and which treat or prevent erectile dysfunction in a subject.Type: ApplicationFiled: April 10, 2012Publication date: August 21, 2014Applicant: INHA INDUSTRY PARTNERSHIP INSTITUTEInventors: Jun Kyu Suh, Ji Kan Ryu, Hai Rong Jin, Young Guen Kwon
-
Patent number: 8450274Abstract: The present invention provides DKK2 and DKK-Fc fusion protein with angiogesis promoting activity and methods of using the same.Type: GrantFiled: April 20, 2011Date of Patent: May 28, 2013Assignee: Theragenetex Co., Ltd.Inventors: Young-Guen Kwon, Jeong-Ki Min
-
Publication number: 20120245110Abstract: The present disclosure relates to a novel vascular leakage inhibitor. The novel vascular leakage inhibitor of the present disclosure inhibits the apoptosis of vascular endothelial cells, inhibits the formation of actin stress fibers induced by VEGF, enhances the cortical actin ring structure, and improves the stability of the tight junctions (TJs) between vascular cells, thereby inhibiting vascular leakage. The vascular leakage inhibitor of the present disclosure has the activity of not only reducing vascular permeability but also recovering the integrity of damaged blood vessels. Accordingly, the vascular leakage inhibitor of the present disclosure can prevent or treat various diseases caused by vascular leakage. Since the vascular leakage inhibitor of the present disclosure is synthesized from commercially available or easily synthesizable cholesterols, it has remarkably superior feasibility of commercial synthesis.Type: ApplicationFiled: October 29, 2010Publication date: September 27, 2012Inventors: Young-Guen Kwon, Young-Ger Suh
-
Patent number: 8067387Abstract: The present invention relates to a method for stimulating angiogenesis using by DKK2 and composition comprising the same. The DKK2 protein of the present invention showed stimulating activities of tube formation on HUVEC, promoting activity of the sprouting of arterial circle tissues and promoting activity of vascular development in the embryo of mouse. Therefore, it can be used as the therapeutics or functional health food for treating and preventing ischemic disease.Type: GrantFiled: May 23, 2007Date of Patent: November 29, 2011Assignee: Theragen Etex Co., LtdInventors: Young-Guen Kwon, Jeong-Ki Min, Chae-Ok Yun, Young-Myeong Kim
-
Publication number: 20110223184Abstract: The present invention provides DKK2 and DKK-Fc fusion protein with angiogesis promoting activity and methods of using the same.Type: ApplicationFiled: April 20, 2011Publication date: September 15, 2011Inventors: Young-Guen KWON, Jeong-Ki MIN
-
Publication number: 20110065176Abstract: The present invention relates to human monoclonal antibodies neutralizing vascular endothelial growth factor receptor and the use thereof. More specifically, relates to human ScFv molecules neutralizing vascular endothelial growth factor receptor, and a composition for inhibiting angiogenesis and a composition for treating cancer, which contain the human ScFv molecules. The disclosed monoclonal antibody neutralizing vascular endothelial growth factor receptor shows excellent neutralizing ability in living cells, compared to that of a commercially available antibody against vascular endothelial growth factor receptor, and shows the ability to neutralize vascular endothelial growth factor receptor not only in humans, but also in mice and rats. Thus, the monoclonal antibody will be useful in anticancer studies and will be highly effective in cancer treatment.Type: ApplicationFiled: June 26, 2007Publication date: March 17, 2011Applicant: Korea Research Institute of BioScience and BioTechnologyInventors: Jin-San Yoo, Weon-Sup Lee, Sang-Ryeol Shim, Mi-Hee Park, Jeong- Eun Kang, Do-Yun Kim, Joon Chul Lee, Dong-Heon Lee, Too-Hyon Cho, Sam-Sook Sul, Young-Guen Kwon, Bo-Jeong Pyun, Kwi-Hwa Kim, Chae-Ok Yun, Nahm-Ju Kim, Jae -Won Jeon, Dong- Sup Lee, Young-Woo Park, Geun - Bae Rha, Hyun-Sook Jang, Hyeon- Mi Yoo, Sung-Woo Kim, Semi Kim, Sang-Seok Koh
-
Publication number: 20110028547Abstract: The present invention relates to a new use of capsiate or dihydrocapsiate, more particularly to a composition for preventing and treating inflammatory disease, angiogenesis-related disease and autoimmune disease or for suppressing immunity comprising capsiate, dihydrocapsiate or a pharmaceutically acceptable salt thereof as an effective ingredient. The composition and immunosuppressant of the present invention may be used for preventing and treating inflammatory disease, angiogenesis-related disease and autoimmune disease, and for suppressing immunity.Type: ApplicationFiled: May 27, 2008Publication date: February 3, 2011Applicant: Catholic University Industry Academic CooperationInventors: Dong Heun Shin, Young Guen Kwon, Bo Jeong Pyun, Tae-Yoon Kim
-
Publication number: 20090317496Abstract: The present invention relates to compositions containing an extract of processed Panax genus plant and saponin compounds isolated therefrom for treat the diseases caused by vascular injury in human or mammal, the method for treating said diseases using thereby and the use thereof. The extract of processed Panax genus plant and saponin compounds isolated therefrom shows suppressive effect on endothelial dysfunction and damage of blood-retinal on HUVEC and retinal vascular endothelial cell. Therefore, it can be used as the therapeutics or functional health food for treating and preventing the diseases caused by vascular injury.Type: ApplicationFiled: September 15, 2006Publication date: December 24, 2009Applicant: GINSENG SCIENCE INC.Inventors: Jeong Hill Park, Hyun Young Kim, Young Guen Kwon, Jeong Hun Kim, Bok Deuk Kim, Young Sun Maeng
-
Publication number: 20090275509Abstract: The present invention relates to a method for stimulating angiogenesis using by DKK2 and composition comprising the same. The DKK2 protein of the present invention showed stimulating activities of tube formation on HUVEC, promoting activity of the sprouting of arterial circle tissues and promoting activity of vascular development in the embryo of mouse. Therefore, it can be used as the therapeutics or functional health food for treating and preventing ischemic disease.Type: ApplicationFiled: May 23, 2007Publication date: November 5, 2009Inventors: Young-Guen Kwon, Jeong-ki Min, Chae-Ok Yun, Young-Myeong Kim